X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (25) 25
oncology (24) 24
female (20) 20
humans (20) 20
aged (19) 19
male (19) 19
middle aged (19) 19
adult (16) 16
care and treatment (14) 14
neoplasms - drug therapy (14) 14
cancer (13) 13
pharmacology & pharmacy (12) 12
pharmacology/toxicology (12) 12
cancer research (11) 11
medicine & public health (11) 11
treatment outcome (9) 9
tumors (9) 9
analysis (8) 8
antineoplastic agents - adverse effects (8) 8
antineoplastic agents - therapeutic use (8) 8
chemotherapy (8) 8
aged, 80 and over (7) 7
antineoplastic agents - administration & dosage (7) 7
antineoplastic agents - pharmacokinetics (7) 7
complications and side effects (7) 7
dose-response relationship, drug (7) 7
maximum tolerated dose (7) 7
neoplasms - pathology (7) 7
research (7) 7
neoplasms - metabolism (6) 6
pharmacokinetics (6) 6
pharmacology (6) 6
protein kinase inhibitors - pharmacokinetics (6) 6
safety (6) 6
solid tumors (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
drug administration schedule (5) 5
medical research (5) 5
neoplasms - enzymology (5) 5
protein kinase inhibitors - administration & dosage (5) 5
protein kinase inhibitors - adverse effects (5) 5
toxicity (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
bevacizumab (4) 4
biomarkers (4) 4
combination therapy (4) 4
fatigue (4) 4
immunotherapy (4) 4
kinases (4) 4
medicine, experimental (4) 4
metastasis (4) 4
mutation (4) 4
patients (4) 4
pembrolizumab (4) 4
proto-oncogene proteins c-akt - antagonists & inhibitors (4) 4
respiratory system (4) 4
therapy (4) 4
young adult (4) 4
administration, oral (3) 3
antibodies (3) 3
antibodies, monoclonal - adverse effects (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antineoplastic agents (3) 3
apoptosis (3) 3
area under curve (3) 3
cancer therapies (3) 3
carboplatin - administration & dosage (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
cell lung-cancer (3) 3
combination (3) 3
cytotoxicity (3) 3
drug dosages (3) 3
drug therapy (3) 3
guidelines (3) 3
heterocyclic compounds, 3-ring - administration & dosage (3) 3
heterocyclic compounds, 3-ring - adverse effects (3) 3
heterocyclic compounds, 3-ring - pharmacokinetics (3) 3
human cancer (3) 3
infusions, intravenous (3) 3
inhibitor (3) 3
lung cancer, non-small cell (3) 3
lung neoplasms - drug therapy (3) 3
map kinase kinase 1 - antagonists & inhibitors (3) 3
map kinase kinase 2 - antagonists & inhibitors (3) 3
mek inhibitor (3) 3
melanoma (3) 3
monoclonal antibodies (3) 3
nausea (3) 3
open-label (3) 3
original (3) 3
original article (3) 3
pathway (3) 3
pharmacodynamics (3) 3
phase i (3) 3
protein kinase inhibitors - therapeutic use (3) 3
stem cells (3) 3
studies (3) 3
viral antibodies (3) 3
abridged index medicus (2) 2
adolescent (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9948, pp. 1109 - 1117
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1497 - 1508
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 21, pp. 2018 - 2028
Journal Article
Journal Article
by Ager, Casey and Reilley, Matthew and Nicholas, Courtney and Bartkowiak, Todd and Jaiswal, Ashvin and Curran, Michael and Albershardt, Tina C and Bajaj, Anshika and Archer, Jacob F and Reeves, Rebecca S and Ngo, Lisa Y and Berglund, Peter and ter Meulen, Jan and Denis, Caroline and Ghadially, Hormas and Arnoux, Thomas and Chanuc, Fabien and Fuseri, Nicolas and Wilkinson, Robert W and Wagtmann, Nicolai and Morel, Yannis and Andre, Pascale and Atkins, Michael B and Carlino, Matteo S and Ribas, Antoni and Thompson, John A and Choueiri, Toni K and Hodi, F. Stephen and Hwu, Wen-Jen and McDermott, David F and Atkinson, Victoria and Cebon, Jonathan S and Fitzharris, Bernie and Jameson, Michael B and McNeil, Catriona and Hill, Andrew G and Mangin, Eric and Ahamadi, Malidi and van Vugt, Marianne and van Zutphen, Mariëlle and Ibrahim, Nageatte and Long, Georgina V and Gartrell, Robyn and Blake, Zoe and Simoes, Ines and Fu, Yichun and Saito, Takuro and Qian, Yingzhi and Lu, Yan and Saenger, Yvonne M and Budhu, Sadna and De Henau, Olivier and Zappasodi, Roberta and Schlunegger, Kyle and Freimark, Bruce and Hutchins, Jeff and Barker, Christopher A and Wolchok, Jedd D and Merghoub, Taha and Burova, Elena and Allbritton, Omaira and Hong, Peter and Dai, Jie and Pei, Jerry and Liu, Matt and Kantrowitz, Joel and Lai, Venus and Poueymirou, William and MacDonald, Douglas and Ioffe, Ella and Mohrs, Markus and Olson, William and Thurston, Gavin and Capasso, Cristian and Frascaro, Federica and Carpi, Sara and Tähtinen, Siri and Feola, Sara and Fusciello, Manlio and Peltonen, Karita and Martins, Beatriz and Sjöberg, Madeleine and Pesonen, Sari and Ranki, Tuuli and Kyruk, Lukasz and Ylösmäki, Erkko and Cerullo, Vincenzo and Cerignoli, Fabio and Xi, Biao and Guenther, Garret and Yu, Naichen and Muir, Lincoln and Zhao, Leyna and Abassi, Yama and Cervera-Carrascón, Víctor and Siurala, Mikko and Santos, João and Havunen, Riikka and Parviainen, Suvi and Hemminki, Akseli and ...
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 11/2016, Volume 4, Issue S1
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 9/2018, Volume 82, Issue 3, pp. 407 - 418
The phase I study characterized the safety, pharmacokinetics, anti-tumor activity, and recommended phase II dose/schedule of LY3164530 in patients with... 
Phase I | Medicine & Public Health | Bispecific | Oncology | Cancer Research | Pharmacology/Toxicology | MET | EGFR | CELL LUNG-CANCER | TRIALS | INHIBITION | ONCOLOGY | ACQUIRED-RESISTANCE | PHARMACOLOGY & PHARMACY | Immunohistochemistry | ErbB Receptors - antagonists & inhibitors | Proto-Oncogene Proteins c-met - blood | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Humans | Middle Aged | Neoplasms - enzymology | Male | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Neoplasm Metastasis | Antibodies, Bispecific - adverse effects | Neoplasms - blood | Proto-Oncogene Proteins c-met - immunology | Antibodies, Bispecific - administration & dosage | ErbB Receptors - immunology | Adult | Female | Aged | Antibodies, Bispecific - blood | Neoplasms - pathology | ErbB Receptors - blood | Viral antibodies | Complications and side effects | Care and treatment | Cancer patients | Epidermal growth factor | Analysis | Colorectal cancer | Stem cells | Antibodies | Skin | Metastasis | Cancer | Interval models | Schedules | Mesenchyme | Toxicity | Colorectal carcinoma | Dermatitis | Metastases | Anticancer properties | Antitumor agents | Immunotherapy | Hypokalemia | Biocompatibility | Inhibition | Hypomagnesemia | Epidermal growth factor receptors | Fatigue | Pharmacology | Disease control | Patients | Biomarkers | Pharmacokinetics | Bispecific antibodies | Original
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 10/2019, Volume 37, Issue 28, pp. 2518 - 2518
PURPOSE Pembrolizumab monotherapy has demonstrated durable antitumor activity in advanced programmed death ligand 1 (PD-L1)-expressing nonsmall-cell lung... 
ONCOLOGY | THERAPY | IMMUNOHISTOCHEMISTRY | RAPID COMMUNICATION
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2014, Volume 20, Issue 22, pp. 5672 - 5685
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2019, Volume 37, Issue 12, pp. 946 - 953
PURPOSE To evaluate the safety, pharmacokinetics, and pharmacodynamics of Hu5F9-G4 (5F9), a humanized IgG4 antibody that targets CD47 to enable phagocytosis.... 
TARGET | PHAGOCYTOSIS | CD47 | ONCOLOGY | RITUXIMAB
Journal Article
The Lancet Respiratory Medicine, ISSN 2213-2600, 04/2019, Volume 7, Issue 4, pp. 347 - 357
The anti-programmed death 1 monoclonal antibody pembrolizumab has shown antitumour activity and is a first-line and second-line treatment option for patients... 
SURVIVAL | SAFETY | RESPIRATORY SYSTEM | 1ST-LINE THERAPY | CHEMOTHERAPY | IMMUNOHISTOCHEMISTRY ASSAY | CRITICAL CARE MEDICINE
Journal Article
by Lundqvist, Andreas and van Hoef, Vincent and Zhang, Xiaonan and Wennerberg, Erik and Lorent, Julie and Witt, Kristina and Sanz, Laia Masvidal and Liang, Shuo and Murray, Shannon and Larsson, Ola and Kiessling, Rolf and Mao, Yumeng and Sidhom, John-William and Bessell, Catherine A and Havel, Jonathan and Schneck, Jonathan and Chan, Timothy A and Sachsenmeier, Eliot and Woods, David and Berglund, Anders and Ramakrishnan, Rupal and Sodre, Andressa and Weber, Jeffrey and Zappasodi, Roberta and Li, Yanyun and Qi, Jingjing and Wong, Philip and Sirard, Cynthia and Postow, Michael and Newman, Walter and Koon, Henry and Velcheti, Vamsidhar and Callahan, Margaret K and Wolchok, Jedd D and Merghoub, Taha and Lum, Lawrence G and Choi, Minsig and Thakur, Archana and Deol, Abhinav and Dyson, Gregory and Shields, Anthony and Haymaker, Cara and Uemura, Marc and Murthy, Ravi and James, Marihella and Wang, Daqing and Brevard, Julie and Monaghan, Catherine and Swann, Suzanne and Geib, James and Cornfeld, Mark and Chunduru, Srinivas and Agrawal, Sudhir and Yee, Cassian and Wargo, Jennifer and Patel, Sapna P and Amaria, Rodabe and Tawbi, Hussein and Glitza, Isabella and Woodman, Scott and Hwu, Wen-Jen and Davies, Michael A and Hwu, Patrick and Overwijk, Willem W and Bernatchez, Chantale and Diab, Adi and Massarelli, Erminia and Segal, Neil H and Ribrag, Vincent and Melero, Ignacio and Gangadhar, Tara C and Urba, Walter and Schadendorf, Dirk and Ferris, Robert L and Houot, Roch and Morschhauser, Franck and Logan, Theodore and Luke, Jason J and Sharfman, William and Barlesi, Fabrice and Ott, Patrick A and Mansi, Laura and Kummar, Shivaani and Salles, Gilles and Carpio, Cecilia and Meier, Roland and Krishnan, Suba and McDonald, Dan and Maurer, Matthew and Gu, Xuemin and Neely, Jaclyn and Suryawanshi, Satyendra and Levy, Ronald and Khushalani, Nikhil and Wu, Jennifer and Zhang, Jinyu and Basher, Fahmin and Rubinstein, Mark and Bucsek, Mark and Qiao, Guanxi and ...
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 11/2016, Volume 4, Issue S1
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2015, Volume 75, Issue 1, pp. 183 - 189
To identify the maximum tolerated dose (MTD) and recommended Phase II dose of MEK/AKT inhibitor combination of trametinib and afuresertib.Eligibility criteria... 
Medicine & Public Health | MEK Inhibitor | Afuresertib | Oncology | Cancer Research | Pharmacology/Toxicology | Combination therapy | AKT Inhibitor | Trametinib | MEK inhibitor | AKT inhibitor | MELANOMA | ONCOLOGY | PATHWAY | MUTATION | PHARMACOLOGY & PHARMACY | HUMAN CANCER | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Thiophenes - administration & dosage | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Early Termination of Clinical Trials | Pyridones - administration & dosage | Multiple Myeloma - drug therapy | Neoplasms - blood | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Multiple Myeloma - enzymology | Pyrazoles - pharmacokinetics | Multiple Myeloma - blood | Pyrazoles - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | MAP Kinase Kinase 1 - antagonists & inhibitors | Pyridones - pharmacokinetics | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasms - enzymology | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Thiophenes - pharmacokinetics | Pyrazoles - administration & dosage | Pyrimidinones - pharmacokinetics | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Aged | Pyridones - therapeutic use | Pyrimidinones - administration & dosage | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Pyridones - adverse effects | Cohort Studies | Complications and side effects | Medical research | Care and treatment | Type 1 diabetes | Analysis | Gastrointestinal diseases | Multiple myeloma | Melanoma | Medicine, Experimental | Aspartate | Nausea | Tumors | Index Medicus
Journal Article